Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896256743> ?p ?o ?g. }
- W2896256743 endingPage "609" @default.
- W2896256743 startingPage "605" @default.
- W2896256743 abstract "Immune checkpoint blockade therapy has been successful in treating some types of cancer but has not shown clinical benefits for treating leukaemia1. This result suggests that leukaemia uses unique mechanisms to evade this therapy. Certain immune inhibitory receptors that are expressed by normal immune cells are also present on leukaemia cells. Whether these receptors can initiate immune-related primary signalling in tumour cells remains unknown. Here we use mouse models and human cells to show that LILRB4, an immunoreceptor tyrosine-based inhibition motif-containing receptor and a marker of monocytic leukaemia, supports tumour cell infiltration into tissues and suppresses T cell activity via a signalling pathway that involves APOE, LILRB4, SHP-2, uPAR and ARG1 in acute myeloid leukaemia (AML) cells. Deletion of LILRB4 or the use of antibodies to block LILRB4 signalling impeded AML development. Thus, LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment. LILRB4 represents a compelling target for the treatment of monocytic AML." @default.
- W2896256743 created "2018-10-26" @default.
- W2896256743 creator A5001011053 @default.
- W2896256743 creator A5002760106 @default.
- W2896256743 creator A5004967316 @default.
- W2896256743 creator A5006929201 @default.
- W2896256743 creator A5006978008 @default.
- W2896256743 creator A5010540700 @default.
- W2896256743 creator A5012895760 @default.
- W2896256743 creator A5018027786 @default.
- W2896256743 creator A5018145110 @default.
- W2896256743 creator A5021742464 @default.
- W2896256743 creator A5025198232 @default.
- W2896256743 creator A5026356376 @default.
- W2896256743 creator A5026884851 @default.
- W2896256743 creator A5027710791 @default.
- W2896256743 creator A5030598774 @default.
- W2896256743 creator A5030995742 @default.
- W2896256743 creator A5031371352 @default.
- W2896256743 creator A5032822369 @default.
- W2896256743 creator A5035676180 @default.
- W2896256743 creator A5037252003 @default.
- W2896256743 creator A5039223843 @default.
- W2896256743 creator A5039468409 @default.
- W2896256743 creator A5040137337 @default.
- W2896256743 creator A5043502860 @default.
- W2896256743 creator A5050089664 @default.
- W2896256743 creator A5051698003 @default.
- W2896256743 creator A5052731834 @default.
- W2896256743 creator A5053969003 @default.
- W2896256743 creator A5056907815 @default.
- W2896256743 creator A5057527087 @default.
- W2896256743 creator A5059881584 @default.
- W2896256743 creator A5060603592 @default.
- W2896256743 creator A5061962242 @default.
- W2896256743 creator A5063390222 @default.
- W2896256743 creator A5071959801 @default.
- W2896256743 creator A5072932805 @default.
- W2896256743 creator A5073448233 @default.
- W2896256743 creator A5076892734 @default.
- W2896256743 creator A5076932676 @default.
- W2896256743 creator A5078732636 @default.
- W2896256743 creator A5084433072 @default.
- W2896256743 creator A5084506385 @default.
- W2896256743 creator A5086303771 @default.
- W2896256743 creator A5088108509 @default.
- W2896256743 creator A5089074892 @default.
- W2896256743 creator A5091421622 @default.
- W2896256743 date "2018-10-01" @default.
- W2896256743 modified "2023-10-17" @default.
- W2896256743 title "LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration" @default.
- W2896256743 cites W135611249 @default.
- W2896256743 cites W1519460121 @default.
- W2896256743 cites W1605315426 @default.
- W2896256743 cites W1687855674 @default.
- W2896256743 cites W1937066674 @default.
- W2896256743 cites W1965336857 @default.
- W2896256743 cites W1965650798 @default.
- W2896256743 cites W1966259152 @default.
- W2896256743 cites W1973765711 @default.
- W2896256743 cites W1988417038 @default.
- W2896256743 cites W2003209323 @default.
- W2896256743 cites W2005574282 @default.
- W2896256743 cites W2018192985 @default.
- W2896256743 cites W2022022565 @default.
- W2896256743 cites W2037389395 @default.
- W2896256743 cites W2044590966 @default.
- W2896256743 cites W2046560815 @default.
- W2896256743 cites W2049489460 @default.
- W2896256743 cites W2052318430 @default.
- W2896256743 cites W2054648595 @default.
- W2896256743 cites W2062108627 @default.
- W2896256743 cites W2062393939 @default.
- W2896256743 cites W2089686312 @default.
- W2896256743 cites W2093455511 @default.
- W2896256743 cites W2105724560 @default.
- W2896256743 cites W2107889871 @default.
- W2896256743 cites W2125384784 @default.
- W2896256743 cites W2130350426 @default.
- W2896256743 cites W2134062610 @default.
- W2896256743 cites W2141919376 @default.
- W2896256743 cites W2144076105 @default.
- W2896256743 cites W2145854562 @default.
- W2896256743 cites W2151793941 @default.
- W2896256743 cites W2195967565 @default.
- W2896256743 cites W2220539909 @default.
- W2896256743 cites W2429878409 @default.
- W2896256743 cites W2563700816 @default.
- W2896256743 cites W2613336296 @default.
- W2896256743 cites W2806760348 @default.
- W2896256743 doi "https://doi.org/10.1038/s41586-018-0615-z" @default.
- W2896256743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6296374" @default.
- W2896256743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30333625" @default.
- W2896256743 hasPublicationYear "2018" @default.
- W2896256743 type Work @default.
- W2896256743 sameAs 2896256743 @default.
- W2896256743 citedByCount "154" @default.
- W2896256743 countsByYear W28962567432019 @default.